Ginkgo Bioworks Holdings, Inc. (DNA) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-26
Business type: Asset play
How it makes money
Commercial and government customers pay for biological R&D services and automation tools.
Customers pay for biological R&D services and automation tools to advance biological programs.
Using AI and reusable data assets allows the company to complete projects with less work, which helps improve the efficiency of the service.
What protects it: the moat
Management claims its automated platform and data assets provide a scale advantage.
Management claims that the company's Autonomous Lab and data assets provide a competitive advantage. The company asserts that its platform improves with each successive project, a benefit that traditional in-house labs do not have.
What growth costs
The company must reinvest heavily in its platform and automation to scale.
Ginkgo invests significant funds to develop its platform, expand its Biosecurity and Automation business units, and perform cell engineering programs.
This includes making capital investments necessary to scale up its business.
What could damage it
Revenue can drop if customers stop their development plans or end their agreements.
A significant portion of revenue comes from services provided to advance specific programs. If a customer decides to stop a project or terminate a contract, Ginkgo loses those service fees.
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.